若根治性前列腺切除术(RP)后患者PSA≥2 ng/mL,或初始放疗后患者PSA≥5 ng/mL时,可重启治疗。 参考资料: 1.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-non-metastatic-castration-sensitive-prostate-cancer-biochemical-recurrence 编辑:Gardenia 审校:Gardenia 执行:Ba...
参考文献: 1.Fizazi K, Shore N, Tammela T L, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide[J]. New England Journal of Medicine, 2020, 383(11): 1040-1049. 2. ESMO 2023: Abstract 1781P. 3. ESMO 2023: Abstract 1780P. 4. Smith MR, Hussain ...
[5] Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2...
我国转移性激素敏感性前列腺癌(mHSPC)患者基线状态复杂,PSA达标率仅约50%[1,2],5年生存率仅约35%[3],严重威胁我国老年男性健康。近年来,达罗他胺等新型雄激素受体抑制剂(ARi)为前列腺癌内分泌治疗提供了更多选择,已成为mHSPC的...
研究表明,无论在前列腺癌非转移还是转移阶段,将PSA控制在0.2 ng/mL均可大幅降低疾病进展和死亡风险[5-8]。因此,无论是非转移还是转移性前列腺癌,都应将PSA控制达标降至0.2 ng/mL以下。 此外,在前列腺癌的不同疾病阶段存在不同PSA水平控制目标,治疗效果还需分别评估[9-11]。
Introduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed prostate cancer, with few reports of ...
A multicenter study of nonmetastatic castration-resistant prostate cancer (nmCRPC) was conducted to identify the optimal cut-off value of prostate-specific antigen (PSA) doubling time (PSADT) that correlated with the prognosis in Japanese nmCRPC. Of the 515 patients diagnosed and treated for nmCRPC...
Abiraterone (AA) is indicated in mRCPC (metastatic castration-resistant prostate cancer) before or after chemotherapy, and in mHSPC (metastatic hormone-sensitive prostate cancer) as first line. A decrease in PSA is associated with improved clinical response and increased survival. Recent studies have...
A false-negative PSA test result can also occur. PSA levels can be low even though you actually have prostate cancer. False-negative test results may give you false assurance. If I choose PSA testing, what are the next steps if you have a raised PSA level?
TRUS biopsy suffers from a significant risk of false negative or misclassification of prostate cancer diagnosis owing to the random nature of sampling of the prostate [14]. The reference standard was performed with knowledge of the index test (PSA) in 16 of 19 studies. Patient populations were ...